• Citer

Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.

par Anderson, Richard A;Cameron, David A;Clatot, Florian;Demeestere, Isabelle ;Lambertini, Matteo ;Nelson, Scott S.M.;Peccatori, Fedro Alessandro
Référence Human reproduction update, 28, 3, page (417-434)
Publication Publié, 2022-05-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Female patients undergoing anticancer treatment are at elevated risk of adverse ovarian outcomes including infertility and premature ovarian insufficiency (POI), which is associated with short- and long-term health risks. Anti-Müllerian hormone (AMH) is a key biomarker of ovarian reserve, but its role prior to and after cancer treatment is less well understood.